An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension.
- Mechanism
- Curator reviewed
Metaraminol acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic & diastolic). Its effect is thought to be associated with the inhibition of adenyl cyclase which leads to an inhibition of the production of cAMP. Another effect of Metaraminol is that it releases norepinephrine from its storage sites indirectly.
- Primary indication
- For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damageCurator reviewed
- Formula / weight
- C9H13NO2 · 167.205 g/mol (avg)
- First approval
- United States, 2024
- Also known as
- 1-Metaraminol · Hydroxynorephedrine · L-Metaraminol · m-Hydroxy norephedrine · m-Hydroxyphenylpropanolamine
Resolves to
WXFIGDLSSYIKKV-RCOVLWMOSA-NSMILESC[C@H](N)[C@H](O)C1=CC(O)=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Metaraminol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account